Søby, S. et al. 2025. Pembrolizumab as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a multi-institutional DAHANCA cohort study. Acta Oncologica. 64, (Sep. 2025), 1269–1275. DOI:https://doi.org/10.2340/1651-226X.2025.44327.